Acasti Pharma, Inc.

Acasti Pharma, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Acasti Pharma, Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Acasti Pharma, Inc. is not a good value stock. Acasti Pharma, Inc. has good growth characteristics. Acasti Pharma, Inc. is a mediocre stock to choose.
Log in to see more information.
Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications...
ACST Fundamental Data by TradingView

News

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of...\n more…

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Simply Wall St There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...\n more…

Acasti Pharma Inc. (NASDAQ:ACST) Sees Significant Decline in Short Interest
Acasti Pharma Inc. (NASDAQ:ACST) Sees Significant Decline in Short Interest

Zolmax Acasti Pharma Inc. (NASDAQ:ACST - Get Free Report) saw a large drop in short interest in the month of August. As of August 15th, there was short interest totalling 500 shares, a drop of 83.9% from...\n more…

Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Update
Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Update

Ticker Report Acasti Pharma Inc. (NASDAQ:ACST - Get Free Report) saw a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 500 shares, a decline of...\n more…

Acasti Pharma Appoints Prashant Kohli as CEO with Incentives
Acasti Pharma Appoints Prashant Kohli as CEO with Incentives

TipRanks Financial Blog Acasti Pharma (ACST) just unveiled an announcement. Acasti Pharma Inc. has signed an employment agreement with Prashant Kohli as its CEO, offering a $500,000 annual...\n more…

Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Down 49.2% in July
Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Down 49.2% in July

Ticker Report Acasti Pharma Inc. (NASDAQ:ACST - Get Free Report) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 3,100 shares, a drop of 49.2% from the...\n more…